MRSA Drugs

World Market Report

MCP13488

EXECUTIVE ENGAGEMENTS

POOL

3647
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

656
Interactions with Platform & by Email

PARTICIPANTS

109
Unique # Participated

VALIDATIONS

32
Responses Validated*

COMPANIES

23
Responses Validated*
* Login for a full stack data experience

DATE

OCT 2022

TABLES

123

PAGES

183

EDITION

7

PRICE

USD 4950

CODE

MCP13488


COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)

STRONG ACTIVE NICHE TRIVIAL

%

VALIDATED RESEARCH *

S A N T
S A N T
S A N T
S A N T
S A N T
S A N T
S A N T
S A N T

* S = Strong; A = Active; N = Niche; T= Trivial (<1%)
* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlassTM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.
View All Companies...

PARTICIPATE NOW!
RESEARCH MODULES EXECUTIVES
  

HIGHLIGHTS & REPORT INDEX

What`s New for 2022?

» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year

Amid the COVID-19 crisis, the global market for MRSA Drugs estimated at US$1 Billion in the year 2020, is projected to reach a revised size of US$1.4 Billion by 2027, growing at a CAGR of 4.2% over the analysis period 2020-2027. Glycopeptides & Lipoglycopeptides, one of the segments analyzed in the report, is projected to record a 4.2% CAGR and reach US$567.1 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Lipopeptides segment is readjusted to a revised 4.6% CAGR for the next 7-year period.
The MRSA Drugs market in the U.S. is estimated at US$306.4 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$246.2 Million by the year 2027 trailing a CAGR of 4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.8% and 3.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4% CAGR.
In the global Oxazolidinones segment, USA, Canada, Japan, China and Europe will drive the 5.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$120.6 Million in the year 2020 will reach a projected size of US$172.3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$154.7 Million by the year 2027.

SELECT PLAYERS

Absynth Biologics; Allergan PLC; AmpliPhi Biosciences Corporation; AstraZeneca PLC; Basilea Pharmaceutica Ltd.; Baxter International, Inc.; Cempra, Inc.; CrystalGenomics Inc.; Debiopharm Group; Galapagos NV; GlaxoSmithKline plc; Innovation Pharmaceuticals Inc.; Kyorin Pharmaceutical Co., Ltd.; Lytix Biopharma AS; Melinta Therapeutics, Inc.; Merck & Co., Inc.; Nabriva Therapeutics US, Inc.; NovaDigm Therapeutics, Inc.; Paratek Pharmaceuticals, Inc.; Pfizer, Inc.; R-Pharm-US LLC; Savara Inc.; Sealife PHARMA GMBH; Sequella, Inc.; The Medicines Company; Theravance Biopharma, Inc. ; XBiotech Inc.

SEGMENTS

» Drug Class (Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin, Other Drug Classes) » Administration Route (Parenteral, Oral) » Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
MRSA Drugs – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Recent Past, Current & Future Analysis for MRSA Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for MRSA Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for MRSA Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Cephalosporin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Tetracycline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Tetracycline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Tetracycline by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World MRSA Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2012 through 2027
World Recent Past, Current & Future Analysis for Glycopeptides & Lipoglycopeptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Glycopeptides & Lipoglycopeptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Glycopeptides & Lipoglycopeptides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Lipopeptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Lipopeptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Lipopeptides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Oxazolidinones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Oxazolidinones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Oxazolidinones by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
UNITED STATES
MRSA Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
USA Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2012, 2021 & 2027
USA Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2012, 2021 & 2027
USA Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
CANADA
Canada Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2012, 2021 & 2027
Canada Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2012, 2021 & 2027
Canada Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
JAPAN
MRSA Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
Japan Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2012, 2021 & 2027
Japan Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2012, 2021 & 2027
Japan Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
CHINA
MRSA Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
China Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2012, 2021 & 2027
China Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2012, 2021 & 2027
China Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
EUROPE
MRSA Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
Europe Recent Past, Current & Future Analysis for MRSA Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe Historic Review for MRSA Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for MRSA Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027
Europe Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2012, 2021 & 2027
Europe Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2012, 2021 & 2027
Europe Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
FRANCE
MRSA Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
France Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2012, 2021 & 2027
France Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2012, 2021 & 2027
France Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
GERMANY
MRSA Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
Germany Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2012, 2021 & 2027
Germany Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2012, 2021 & 2027
Germany Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
ITALY
Italy Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2012, 2021 & 2027
Italy Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2012, 2021 & 2027
Italy Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
UNITED KINGDOM
MRSA Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
UK Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2012, 2021 & 2027
UK Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2012, 2021 & 2027
UK Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
REST OF EUROPE
Rest of Europe Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2012, 2021 & 2027
Rest of Europe Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2012, 2021 & 2027
Rest of Europe Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
ASIA-PACIFIC
MRSA Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Asia-Pacific Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2012, 2021 & 2027
Asia-Pacific Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2012, 2021 & 2027
Asia-Pacific Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
REST OF WORLD
Rest of World Recent Past, Current & Future Analysis for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for MRSA Drugs by Drug Class - Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for MRSA Drugs by Drug Class - Percentage Breakdown of Value Sales for Glycopeptides & Lipoglycopeptides, Lipopeptides, Oxazolidinones, Tetracycline, Cephalosporin and Other Drug Classes for the Years 2012, 2021 & 2027
Rest of World Recent Past, Current & Future Analysis for MRSA Drugs by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for MRSA Drugs by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for MRSA Drugs by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2012, 2021 & 2027
Rest of World Recent Past, Current & Future Analysis for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for MRSA Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for MRSA Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com